Business
Zydus Lifesciences Limited Press Release Jul 23 2026
Zydus Lifesciences Limited has informed the Exchange regarding a press release dated July 23, 2026, titled "Zydus receives approval for Phase III trial of Desidustat in patients with Sickle Cell Disease, to be conducted in collaboration with ICMR".
About this update from Zydus Lifesciences Limited
Zydus Lifesciences Limited has informed the Exchange regarding a press release dated July 23, 2026, titled "Zydus receives approval for Phase III trial of Desidustat in patients with Sickle Cell Disease, to be conducted in collaboration with ICMR". View Attachment
View stock analysis, news, and events for Zydus Lifesciences Limited